Provexis (PXS) AI Stock Analysis

• Market Cap: £13.43M
• Dividend Yield: N/A
• Average Volume (3M): 426.62K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.06
• Revenue Growth: 61.13%
• EPS Growth: 33.33%
• Country: UK
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 2,345,891,400
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 426,617
• PEG Ratio: -0.45
• Price to Book (P/B): 18.37
• Price to Sales (P/S): 16.59
• P/FCF Ratio: -69.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: ―

Provexis demonstrates notable revenue growth and a strong balance sheet with no debt, but struggles with profitability and cash flow challenges. Technical indicators show positive momentum, which provides some optimism. However, the negative P/E ratio and absence of dividend yield suggest caution in its valuation. Overall, the stock reflects moderate potential, with significant risks in financial performance.

Positive Factors

Revenue Growth

Provexis's strong revenue growth indicates successful product adoption and market expansion, which can drive long-term business sustainability and competitiveness in the nutraceutical sector.

Balance Sheet Health

A robust balance sheet with no debt provides Provexis with financial stability, reducing risk and offering flexibility for future investments and strategic initiatives.

Business Model Strength

The licensing-based business model ensures recurring revenue streams and scalability, leveraging intellectual property to drive growth and maintain competitive advantage in the nutraceutical market.

Negative Factors

Profitability Challenges

Ongoing net losses highlight operational inefficiencies and challenge Provexis's ability to achieve sustainable profitability, necessitating cost management and strategic adjustments.

Cash Flow Challenges

Negative free cash flow growth suggests cash outflows exceed inflows, impacting liquidity and limiting Provexis's capacity to fund operations and invest in growth opportunities.

Net Profit Margin

A negative net profit margin indicates that Provexis is not efficiently converting revenue into profit, which could hinder its ability to reinvest in the business and sustain long-term growth.

Provexis Business Overview & Revenue Model

Company Description

Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.

How the Company Makes Money

Provexis makes money primarily through the commercialization of its Fruitflow technology. The company generates revenue by licensing Fruitflow to manufacturers and distributors in the food and dietary supplement industries, allowing them to incorporate the ingredient into their products. Additionally, Provexis engages in collaborative partnerships and agreements with other companies to co-develop and market new products that incorporate its proprietary technology. These partnerships often involve upfront payments, milestone payments, and royalties based on product sales. The company's focus on intellectual property and innovation ensures a recurring revenue stream through licensing deals and collaborative ventures.

Provexis Financial Statement Overview

Summary

Provexis shows promising revenue growth but struggles with profitability and cash flow. The balance sheet remains robust with no debt, offering some financial stability. However, the company must address cash flow inefficiencies and manage operational costs to improve its financial health and sustainability in the long run.

Income Statement

The company has shown significant revenue growth, with a 105.68% increase from the previous year. However, profitability remains a concern with consistent net losses. The gross profit margin is 35.38%, indicating some efficiency in managing production costs, but the net profit margin is negative at -73.10%, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows strong equity, with a debt-to-equity ratio of 0, indicating no financial leverage. The equity ratio stands at 145.48%, demonstrating a strong capital base relative to total assets. However, decreased stockholders' equity over the years suggests potential concerns about future capital sustainability.

Cash Flow

Cash flow analysis indicates a challenging situation with negative free cash flow growth, highlighting cash outflows exceeding inflows. The operating cash flow to net income ratio is 0.33, suggesting inefficient cash conversion from net income. The company needs to improve cash generation from operations.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	1.20M	801.96K	389.92K	426.17K	505.33K	347.94K
Gross Profit	419.48K	283.80K	294.42K	380.05K	456.19K	312.15K
EBITDA	-326.69K	-603.59K	0.00	0.00	0.00	0.00
Net Income	-478.29K	-586.24K	-385.24K	-224.25K	-341.01K	-406.23K
Balance Sheet
Total Assets	822.39K	498.04K	845.99K	1.13M	1.29M	468.76K
Cash, Cash Equivalents and Short-Term Investments	478.20K	189.36K	379.12K	863.87K	1.08M	291.33K
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	471.01K	307.45K	188.34K	157.91K	150.68K	150.08K
Stockholders Equity	885.14K	724.34K	1.19M	1.50M	1.66M	814.37K
Cash Flow
Free Cash Flow	-112.82K	-191.50K	-519.85K	-213.79K	-262.32K	-334.64K
Operating Cash Flow	-112.82K	-191.50K	-519.85K	-213.54K	-262.07K	-334.64K
Investing Cash Flow	1.46K	1.73K	887.00	78.00	-250.00	399.00
Financing Cash Flow	270.74K	0.00	35.10K	1.05M	1.05M	300.33K

Provexis Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.65
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PXS, the sentiment is Positive. The current price of 0.65 is above the 20-day moving average (MA) of 0.61, above the 50-day MA of 0.61, and above the 200-day MA of 0.62, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 57.23 is Neutral, neither overbought nor oversold. The STOCH value of 73.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:PXS.

Provexis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STX	63 Neutral	£73.26M	-3.71	-396.71%	―	93.48%	51.18%
PXS	55 Neutral	£13.43M	-28.25	-51.21%	―	61.13%	33.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Provexis Corporate Events

Provexis Grants Options and Warrants to CEO and Consultants

Provexis plc announced the grant of 56,000,000 options and 58,730,000 warrants over ordinary shares to its CEO, Ian Ford, and to certain scientific, sales, and marketing consultants. This move follows discussions with the company’s larger shareholders and is aimed at aligning management and consultant incentives with company performance, potentially impacting up to 10% of the company’s issued share capital. The grant of options to Ian Ford is a related party transaction, with the directors, excluding Ford, deeming the terms fair and reasonable for shareholders.